1
Jonathan Barasch, Andong Qiu: Mutant NGAL proteins and uses thereof. THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, Wilmer Cutler Pickering Hale and Dorr, April 18, 2017: US09624281

In one aspect the present invention is directed to mutant NGAL proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess ...


2
Jonathan Barasch, Nicholas Barasch: High molecular weight Ngal as a biomarker for chronic kidney disease. The Trustees of Columbia University in the City of New York, Wilmer Cutler Pickering Hale and Dorr, November 26, 2013: US08592170

A high molecular weight form of Ngal is provided which can be used to diagnose chronic kidney disease. High molecular weight Ngal is about 75 kDa to about 350 kDa, and comprises non-Ngal proteins, such as polymeric immunoglobulin receptor, alpha-2-macroglobulin and immunoglobulin heavy chain. Method ...


3
Kai Schmidt Ott, Jonathan Barasch, Jun Yang: Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage. The Trustees Of Columbia University In The City Of New York, WilmerHale Columbia University, April 17, 2008: US20080090765-A1

The invention is directed to compositions comprising two or more compounds selected from the group consisting of stem cell factor, cytokine like factor-1, CXCL14, FRAS1, neuropeptide Y, Semaphorin 3C, Cyr 61, USAG-1, IGF-BP2, WNT 6, WNT 9B, SHH, BMP-7, kit ligand, SOSTDC1, semaphorin 4D, NME3, lamin ...


4
Jonathan Barasch, Nicholas Barasch: High molecular weight ngal as a biomarker for chronic kidney disease. April 21, 2011: US20110091912-A1

A high molecular weight form of Ngal is provided which can be used to diagnose chronic kidney disease. High molecular weight Ngal is about 75 kDa to about 350 kDa, and comprises non-Ngal proteins, such as polymeric immunoglobulin receptor, alpha-2-macroglobulin and immunoglobulin heavy chain. Method ...


5
Jonathan BARASCH, Thomas L NICKOLAS: Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction. WilmerHale Columbia University, September 16, 2010: US20100233739-A1

In one embodiment, the present invention is directed to methods for diagnosis of urinary tract obstruction (UTO), and to methods for distinguishing between unilateral and bilateral UTO. In some aspects, the diagnostic methods of the invention are based on determining whether a bodily fluid sample, s ...


6
Jonathan BARASCH, Thomas L NICKOLAS: Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis. WilmerHale Columbia University, September 16, 2010: US20100233740-A1

In one embodiment, the present invention is directed to methods for diagnosis of acute kidney injury (AKI) and hepatorenal syndrome (HRS) in cirrhosis patients, and to methods for distinguishing between AKI and/or HRS and/or other kidney diseases in cirrhosis subjects. In another embodiment, the pre ...


7
Vikas P Sukhatme, S Ananth Karumanchi, Pankaj Seth, Junichi Hanai, Tadanori Mammoto, Jonathan Barasch, Kiyoshi Mori: Lipocalin 2 for the Treatment, Prevention, and Management of Cancer Metastasis, Angiogenesis, and Fibrosis. Clark & Elbing, December 10, 2009: US20090305963-A1

The invention features methods and compositions for treating and preventing cancer metastasis, angiogenic disorders, and fibrotic disorders using lipocalin 2 compounds.


8
Jonathan Barasch, Neal Paragas: Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan). The Trustees Of Columbia University In The City Of New York, April 5, 2012: US20120083421-A1

The present invention is directed to methods for diagnosis of HIVAN, and to methods for distinguishing between HIVAN and other kidney diseases, based on the presence in a bodily fluid, such as urine, of a level of NGAL protein that exceeds a threshold level. The present invention is also directed to ...


9
Jonathan Barasch, Catherine Forster, Thomas L Nickolas, Neal Paragas: Methods and compositions for diagnosis of urosepsis and urinary tract infection. The Trustees of Columbia University in the City of New York, August 23, 2012: US20120214177-A1

Methods for diagnosis of and distinguishing between, urosepsis, sepsis, and urinary tract infections (UTIs) are disclosed The diagnostic methods are based on determining the level of NGAL protein in a bodily fluid sample, such as urine sample.


10
Jonathan Barasch, Shixian Deng, Guanhu Bao, Donald W Landry: Ngal-binding siderophores and use thereof to treat iron deficiency and iron overload. November 3, 2011: US20110268818-A1

The invention provides compositions comprising a lipocalin, such as NGAL, and a mammalian siderophore that are useful as iron chelators and iron donors. The invention also provides mammalian siderophore compounds of Formula (I): The invention further provides, methods of treatment and methods of dia ...



Click the thumbnails below to visualize the patent trend.